ALKERMES reported $459.09M in Trade Debtors for its fiscal quarter ending in September of 2026.





Trade Debtors Change Date
AbbVie USD 13.82B 1.34B Jun/2026
Acadia Pharmaceuticals USD 178.32M 11.98M Sep/2026
ALKERMES USD 459.09M 2.61M Sep/2026
Amgen USD 10.35B 126M Sep/2026
Biogen USD 2.38B 15.8M Sep/2026
BioMarin Pharmaceutical USD 1.08B 15.31M Sep/2026
Bristol-Myers Squibb USD 12.85B 976M Sep/2026
Coherus Biosciences USD 18.42M 232.08M Dec/2025
Eli Lilly USD 23.48B 2.3B Jun/2026
Gilead Sciences USD 5.06B 314M Jun/2026
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Ionis Pharmaceuticals USD 88M 29.15M Sep/2026
J&J USD 19.05B 3.49B Jun/2026
Malin Corporation EUR 500K 300K Dec/2024
Merck USD 12.56B 354M Jun/2026
Nektar Therapeutics USD 3.6M 1.82M Mar/2026
Neurocrine Biosciences USD 957.3M 70.3M Sep/2026
Otsuka Holdings JPY 586.22B 9.17B Sep/2026
Ovoca Bio EUR 53K 14K Dec/2025
Pfizer USD 17.57B 1.38B Sep/2026
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Vertex Pharmaceuticals USD 2.31B 176.7M Sep/2026